Article
Atlanta--Fewer people are dying from prostate and other genitourinarycancers. But ask why that is, and you'll have a difficult time finding aconsensus among epidemiologists, urologists, and others.
Case study: 69-year-old Black man with mHSPC
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
Experts share insights on next-generation NMIBC therapies
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer